Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among […]
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been given an average rating of “Moderate Buy” by the sixteen research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average […]
Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $28.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 27.85% from the stock’s previous close. […]
Exelixis (NASDAQ:EXEL – Free Report) had its price objective increased by TD Cowen from $25.00 to $27.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other brokerages also recently weighed in on EXEL. TheStreet raised shares of Exelixis from a […]
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]